RUNDC3A

RUNDC3A (RPIP8) is a RUN-domain-containing protein that functions as a specific GTP-dependent effector of the small GTPase Rap2A, interacting selectively with the GTP-bound form and requiring an intact Rap2A effector domain (PMID:9523700). The Rap2 interaction is mediated by its RUN domain, whose 2.0 Å crystal structure reveals eight anti-parallel alpha-helices forming a hydrophobic core and a conserved positively charged surface that constitutes the likely nucleotide-dependent GTPase-binding interface (PMID:16928684). In neuroendocrine carcinoma contexts, RUNDC3A acts as an upstream regulator of SNAP25, which stabilizes AKT by modulating its monoubiquitination and extending AKT protein half-life, thereby driving tumor progression and chemoresistance across gastric, intestinal, lung, and pancreatic neuroendocrine carcinomas (PMID:35752613, PMID:36182960). Beyond these findings, the mechanism connecting RUNDC3A's Rap2 effector function to its role in the SNAP25/AKT axis has not been characterized in the available corpus.

1. 1998 High

   Established RUNDC3A as a bona fide effector of an active small GTPase, defining its first molecular function as a GTP-state-selective Rap2A binding partner.

   Evidence Yeast two-hybrid screen confirmed by in vitro binding with purified proteins and co-immunoprecipitation from transfected HIT-T15 cells

   PMID:9523700

   Open questions at the time

   • Downstream consequence of Rap2A binding not defined
   • Cellular process engaged by the Rap2A-RUNDC3A complex unknown
   • Domain responsible for the interaction not yet mapped
2. 2006 High

   Resolved the structural basis of GTPase recognition, identifying the RUN domain fold and a conserved positively charged surface as the nucleotide-dependent Rap2-binding interface.

   Evidence 2.0 Å crystal structure (MAD) of the RUN domain of an RPIP8/RUNDC3A homolog, NMR fragment mapping, and in vitro nucleotide-dependent Rap2B binding

   PMID:16928684

   Open questions at the time

   • Structure solved for a homolog rather than RUNDC3A itself
   • No co-crystal of the RUN domain bound to Rap2
   • Functional output downstream of binding still undefined
3. 2022 Medium

   Placed RUNDC3A in a disease-relevant signaling axis, showing it acts upstream of SNAP25 to stabilize AKT and promote chemoresistance in neuroendocrine carcinomas.

   Evidence Loss-of-function (knockdown) in GNEC cell lines and in vivo, transcriptome profiling, protein half-life Western blots, and co-IP for the SNAP25-AKT interaction; replicated across multiple neuroendocrine carcinoma types

   PMID:35752613 PMID:36182960

   Open questions at the time

   • Molecular mechanism by which RUNDC3A regulates SNAP25 not defined
   • Whether the Rap2A effector function contributes to the SNAP25/AKT axis is unaddressed
   • Direct vs indirect regulation of SNAP25 not distinguished

• How RUNDC3A's role as a Rap2A GTPase effector mechanistically connects to its regulation of the SNAP25/AKT axis in neuroendocrine cancer remains unresolved.
• No link established between Rap2 effector activity and SNAP25 regulation
• No physiological (non-cancer) cellular role characterized
• Endogenous interactome beyond Rap2 and SNAP25 unknown